| Multiple Myeloma
Elrexfio vs Darzalex Faspro
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Elrexfio vs Darzalex Faspro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDarzalex Faspro has a higher rate of injection site reactions vs Elrexfio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Darzalex Faspro but not Elrexfio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Elrexfio
Darzalex Faspro
At A Glance
SC injection
Weekly to every 4 weeks
BCMA-directed T-cell engager
SC injection
Weekly, then every 2 weeks, then every 4 weeks
CD38-directed monoclonal antibody
Indications
- Multiple Myeloma
- Multiple Myeloma
- Smoldering myeloma
- Light chain (AL) amyloidosis
Dosing
Multiple Myeloma Step-up SC dosing: 12 mg on Day 1, 32 mg on Day 4, then 76 mg weekly starting Day 8 through week 24; for responders, transitions to 76 mg every 2 weeks (weeks 25-48), then 76 mg every 4 weeks (week 49 onward); continue until disease progression or unacceptable toxicity.
Multiple Myeloma 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until disease progression. Dosing schedule varies by combination regimen (with lenalidomide-dexamethasone, bortezomib-melphalan-prednisone, bortezomib-thalidomide-dexamethasone, bortezomib-lenalidomide-dexamethasone, bortezomib-dexamethasone, pomalidomide-dexamethasone, or carfilzomib-dexamethasone) or as monotherapy.
Smoldering myeloma 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until diagnosis of multiple myeloma or maximum 3 years.
Light chain (AL) amyloidosis 1,800 mg daratumumab and 30,000 units hyaluronidase SC into abdomen over 3-5 minutes in combination with bortezomib-cyclophosphamide-dexamethasone. Weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks until disease progression or maximum 2 years.
Contraindications
—
- Severe hypersensitivity to daratumumab, hyaluronidase, or any component of the formulation
Adverse Reactions
Most common (>=20%) CRS, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, pyrexia
Serious Pneumonia, sepsis, CRS, upper respiratory tract infection, acute kidney injury, urinary tract infection, COVID-19, encephalopathy, pyrexia, febrile neutropenia
Most common (>=20%) Upper respiratory tract infection, fatigue, peripheral neuropathy, musculoskeletal pain, constipation, diarrhea, insomnia, rash, edema, pyrexia, nausea, cough, dyspnea, sensory neuropathy, injection site reactions, infusion reactions, headache, decreased appetite, sleep disorder
Serious Pneumonia, cardiac failure, sepsis, thromboembolism, COVID-19, neutropenia, thrombocytopenia, arrhythmia, cardiac arrest, herpes zoster, hepatitis B reactivation, cytomegalovirus infection, listeriosis, atrial fibrillation, pancreatitis, pulmonary edema, anaphylactic reaction
Pharmacology
Elranatamab-bcmm is a bispecific BCMA-directed CD3 T-cell engaging antibody that simultaneously binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and cytolysis of BCMA-expressing cells.
Daratumumab is a CD38-directed IgG1 kappa monoclonal antibody that induces tumor cell death through multiple immune-mediated mechanisms including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and direct apoptosis via Fc-mediated crosslinking.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Elrexfio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Darzalex Faspro
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Elrexfio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Darzalex Faspro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Elrexfio
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Darzalex Faspro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Multiple Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Amyloidosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ElrexfioView full Elrexfio profile
Darzalex FasproView full Darzalex Faspro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.